DUBLIN–(BUSINESS WIRE)–The “Respiratory Collaboration and Licensing Deals 2016-2023” report has been added to ResearchAndMarkets.com’s offering.
Respiratory Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the respiratory deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of respiratory deals from 2016 to 2023. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The report also includes numerous table and figures that illustrate the trends and activities in respiratory deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z and technology type.
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter Highlights
The initial chapters of this report provide an orientation of respiratory dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in respiratory dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the respiratory field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in respiratory dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of respiratory deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of respiratory deals listed by therapeutic target.
Key benefits
- Understand deal trends since 2016
- Browse respiratory collaboration and licensing deals
- Benchmark analysis – identify market value of transactions
- Financials terms – upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents – insights into deal structures
- Due diligence – assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in respiratory dealmaking
2.1. Introduction
2.2. Respiratory partnering over the years
2.3. Respiratory partnering by deal type
2.4. Respiratory partnering by industry sector
2.5. Respiratory partnering by stage of development
2.6. Respiratory partnering by technology type
2.7. Respiratory partnering by therapeutic indication
Chapter 3 – Financial deal terms for respiratory partnering
3.1. Introduction
3.2. Disclosed financials terms for respiratory partnering
3.3. Respiratory partnering headline values
3.4. Respiratory deal upfront payments
3.5. Respiratory deal milestone payments
3.6. Respiratory royalty rates
Chapter 4 – Leading respiratory deals and dealmakers
4.1. Introduction
4.2. Most active in respiratory partnering
4.3. List of most active dealmakers in respiratory
4.4. Top respiratory deals by value
Chapter 5 – Respiratory contract document directory
5.1. Introduction
5.2. Respiratory partnering deals where contract document available
Chapter 6 – Respiratory dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by respiratory therapeutic target
Deal Directory
Deal directory – Respiratory deals by company A-Z 2016 to 2023
Deal directory – Respiratory deals by technology type 2016 to 2023
Companies Mentioned
- Alnylam Pharmaceuticals
- Vortran Medical
- Sichuan University
- Lung and Blood Institute
- Food and Drug Administration (FDA)
- Bill and Melinda Gates Foundation
- Zhejiang Medicine
- Jubilant DraxImage
- Enzyvant Science
- Altavant Sciences
- Biostar Pharmaceuticals
- Scholar Rock
- Monopar Therapeutics
- Wockhardt
- Innovare
- Celularity
- Highmark Blue Shield
- Highmark Health
- Glenmark Pharmaceuticals
- 4D Pharma
- BESPharma
- IR Pharma
- SI Pharmaceuticals
- Wal-Mart
- Sanovas
- Amyndas Pharmaceuticals
- Tunitas Therapeutics
- Innovata HK
- Medidata Solutions
- Advocate Health Care
- Innovate UK
- Foundation for Sarcoidosis Research
- Simulations Plus
- Innovative Genomics Initiative (IGI)
- Innovative Medicines Initiative (IMI)
- Laboratory Corporation of America
- Novavax
- Dynavax Technologies
- Pharmaxis
- Scarab Genomics
- Punjab Province
For more information about this report visit https://www.researchandmarkets.com/r/69h21v
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
